167 related articles for article (PubMed ID: 38341510)
21. mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.
Wu H; He D; Biswas S; Shafiquzzaman M; Zhou X; Charron J; Wang Y; Nayak BK; Habib SL; Liu H; Li B
Cancer Res; 2021 Jun; 81(12):3174-3186. PubMed ID: 33863779
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.
Bailey ST; Zhou B; Damrauer JS; Krishnan B; Wilson HL; Smith AM; Li M; Yeh JJ; Kim WY
PLoS One; 2014; 9(9):e104413. PubMed ID: 25180793
[TBL] [Abstract][Full Text] [Related]
23. Pathologic characterization of renal epithelial neoplasms arising in nonfunctioning kidneys.
Lin X; Goyal R; Yang XJ
Hum Pathol; 2020 Mar; 97():1-7. PubMed ID: 31857138
[TBL] [Abstract][Full Text] [Related]
24. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
25. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma.
Cui L; Zhou H; Zhao H; Zhou Y; Xu R; Xu X; Zheng L; Xue Z; Xia W; Zhang B; Ding T; Cao Y; Tian Z; Shi Q; He X
BMC Cancer; 2012 Nov; 12():546. PubMed ID: 23173671
[TBL] [Abstract][Full Text] [Related]
27. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
[TBL] [Abstract][Full Text] [Related]
28. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
29. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
[TBL] [Abstract][Full Text] [Related]
30. Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma.
Gargalionis AN; Sarlani E; Stofas A; Malakou LS; Adamopoulos C; Bamias A; Boutati E; Constantinides CA; Stravodimos KG; Piperi C; Papavassiliou AG; Korkolopoulou P
Cancer Lett; 2020 Oct; 489():135-143. PubMed ID: 32561414
[TBL] [Abstract][Full Text] [Related]
31. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
[TBL] [Abstract][Full Text] [Related]
32. Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death.
Makhov P; Golovine K; Teper E; Kutikov A; Mehrazin R; Corcoran A; Tulin A; Uzzo RG; Kolenko VM
Br J Cancer; 2014 Feb; 110(4):899-907. PubMed ID: 24434432
[TBL] [Abstract][Full Text] [Related]
33. PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade.
Liu Z; Chen X; Wang Y; Peng H; Wang Y; Jing Y; Zhang H
J Biol Chem; 2014 Oct; 289(43):29739-49. PubMed ID: 25164809
[TBL] [Abstract][Full Text] [Related]
34. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
35. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma.
Cho DC; Cohen MB; Panka DJ; Collins M; Ghebremichael M; Atkins MB; Signoretti S; Mier JW
Clin Cancer Res; 2010 Jul; 16(14):3628-38. PubMed ID: 20606035
[TBL] [Abstract][Full Text] [Related]
37. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
[TBL] [Abstract][Full Text] [Related]
38. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
[TBL] [Abstract][Full Text] [Related]
39. Features and outcomes of renal cell carcinoma of native kidneys in renal transplant recipients.
Klatte T; Seitz C; Waldert M; de Martino M; Kikic Z; Böhmig GA; Haitel A; Schmidbauer J; Marberger M; Remzi M
BJU Int; 2010 May; 105(9):1260-5. PubMed ID: 19818071
[TBL] [Abstract][Full Text] [Related]
40. Preventive Role of mTOR Inhibitor in Post-Kidney Transplant Urothelial Carcinoma.
Chang YL; Lee HC; Luo HL; Chen YT; Chiang PH; Cheng YT
Transplant Proc; 2019 Oct; 51(8):2731-2734. PubMed ID: 31447189
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
